Patents by Inventor Aleem Gangjee

Aleem Gangjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same
    Patent number: 10000498
    Abstract: Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula I: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: June 19, 2018
    Assignee: Duquesne University of the Holy Spirit
    Inventors: Aleem Gangjee, Larry H. Matherly
  • TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF
    Publication number: 20180162863
    Abstract: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.
    Type: Application
    Filed: January 19, 2018
    Publication date: June 14, 2018
    Applicant: Duquesne University of the Holy Ghost
    Inventor: Aleem Gangjee
  • Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
    Patent number: 9994586
    Abstract: The present invention provides a compound of Formula XXVIII: werein R1is H or CH3, and optionally including a salt or a hydrate of said compound.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: June 12, 2018
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
    Patent number: 9987283
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 5, 2018
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF
    Publication number: 20180127434
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 10, 2018
    Applicant: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof
    Publication number: 20180118695
    Abstract: The present invention provides substituted cyclopenta and cyclopentyl pyrimidine bicyclic compounds of Formula III, and pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Application
    Filed: March 9, 2017
    Publication date: May 3, 2018
    Applicant: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT
    Publication number: 20180105536
    Abstract: Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.
    Type: Application
    Filed: July 25, 2017
    Publication date: April 19, 2018
    Applicant: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
    Patent number: 9896455
    Abstract: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: February 20, 2018
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS
    Publication number: 20170369500
    Abstract: The present invention provides conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compounds and pharmaceutical compositions comprising these compounds. Preferably, the compounds exhibit dual inhibition of microtubule assembly and receptor tyrosine kinases. Methods of treating cancer comprising administering a therapeutically effective amount of at least one conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compound to a patient is disclosed.
    Type: Application
    Filed: December 16, 2015
    Publication date: December 28, 2017
    Applicant: DUQUESNE UNIVERSITY OF THE HOLY SPIRIT
    Inventor: ALEEM GANGJEE
  • Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
    Patent number: 9802955
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: October 31, 2017
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents
    Patent number: 9777012
    Abstract: Compounds of Formula I: and compounds of Formula II: are provided. Pharmaceutical compositions comprising either the compound of Formula I or Formula II are disclosed. Methods of treating patients having cancer are provided by administering to the patient a therapeutically effective amount of one or more compounds having Formula I or Formula II to treat the patient. The compounds of Formula I or II are preferably conformationally restricted furo[2,3-d]pyrimidines having dual inhibition of microtubule assembly and receptor tyrosine kinases.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 3, 2017
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE
    Publication number: 20170260190
    Abstract: This invention provides substituted pyrimidine compounds having the formula: wherein X is absent, CH2, S, or O, and R is an alkyl group having from one to ten carbon atoms, and optionally salts, hydrates, or solvates thereof, that are useful in treating a patient having a disease or cancer. The compounds of this invention are useful as multi-enzyme antifolates selectively targeting the folate receptor (FR). Further, a method of making 5- and 6-substituted cyclopenta[d]pyrimidine for nonclassical and classical antifolates as TS and DHFR inhibitors is provided.
    Type: Application
    Filed: April 5, 2017
    Publication date: September 14, 2017
    Applicants: Duquesne University of the Holy Spirit, Wayne State University
    Inventors: Aleem Gangjee, Larry H. Matherly
  • PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20170253612
    Abstract: The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH2, and optionally comprising a pharmaceutically acceptable salt, hydrate, or solvate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Application
    Filed: April 5, 2017
    Publication date: September 7, 2017
    Applicant: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof
    Publication number: 20170246170
    Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Application
    Filed: December 13, 2016
    Publication date: August 31, 2017
    Inventor: Aleem Gangjee
  • Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
    Patent number: 9732090
    Abstract: Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: August 15, 2017
    Assignee: Duquesne University of the Holy Ghost
    Inventor: Aleem Gangjee
  • Pyrimidine compounds and pyrimido indole compounds and methods of use
    Patent number: 9688690
    Abstract: The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH2, and optionally comprising a pharmaceutically acceptable salt, hydrate, or solvate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: June 27, 2017
    Assignee: Duquesne University of the Holy Ghost
    Inventor: Aleem Gangjee
  • Substituted pyrimidine compounds and methods of use and manufacture
    Patent number: 9650384
    Abstract: This invention provides substituted pyrimidine compounds having the formula: wherein X is absent, CH2, S, or O, and R is an alkyl group having from one to ten carbon atoms, and optionally salts, hydrates, or solvates thereof, that are useful in treating a patient having a disease or cancer. The compounds of this invention are useful as multi-enzyme antifolates selectively targeting the folate receptor (FR). Further, a method of making 5- and 6-substituted cyclopenta[d]pyrimidine for nonclassical and classical antifolates as TS and DHFR inhibitors is provided.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: May 16, 2017
    Assignee: Duquesne University of the Holy Ghost
    Inventors: Aleem Gangjee, Larry H. Matherly
  • Selective Proton Coupled Folate Transporter and Folate Receptor, and Garftase Inhibitor Compounds and Methods of Using the Same
    Publication number: 20170114066
    Abstract: Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula I: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.
    Type: Application
    Filed: November 3, 2016
    Publication date: April 27, 2017
    Inventors: Aleem Gangjee, Larry H. Matherly
  • Substituted cyclopenta pyrimidine bicyclic compounds having antitmitotic and/or antitumor activity methods of use thereof
    Patent number: 9624178
    Abstract: The present invention provides substituted cyclopenta and cyclopentyl pyrimidine bicyclic compounds of Formula III, and 5,6-saturated and unsaturated and pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: April 18, 2017
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same
    Publication number: 20170050978
    Abstract: The present invention provides a compound of Formula I: wherein R is H, a methyl group, an ethyl group, a n-propyl group, an iso-propyl group, or a n-butyl group; and R1 is H, a 4?-methyl group, a 4?-OH, a 4?-OMe group, a 2?,3?-C2H4 group, a; 3?,4?-C2H4 group, a 3?,4?-diF, a 3?,4?,5?-triF, or a 4?-OCF3; and optionally including a salt or a hydrate of said compound, and further provides a pharmaceutical composition comprising the compound of Formula I and one or more acceptable pharmaceutical carriers. A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutical composition comprising a compound of Formula I and one or more acceptable pharmaceutical carriers to the patient is disclosed.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 23, 2017
    Inventor: Aleem Gangjee